COVID-19 kasalligi bilan bogʻliq hayz-ovarial funksiyasi buzilishlari mavjud ayollarda endometriy reseptorlarining holati

Abstract

Xulosa. Tadqiqotga 60 nafar COVID-19 kasalligi bilan bogʻliq xayz davriyligini buzilishlari mavjud ayollar kiritildi. Undan 20 nafari COVID-19 kasalligi yengil formasi bilan, 20 nafari COVID-19 kasalligi oʻrtacha ogʻirlikdagi formasi bilan, 20 nafari COVID-19 kasalligi ogʻir formasi bilan bemorlarga boʻlindi. Nazorat guruxini 20 nafar sogʻlom ayollar tashkil qildi. COVID-19 kasalligi bilan bogʻliq hayz-ovarial funksiya buzilishlari mavjud ayollar endometriysida estrogen (ER) va progesteron (PR) retseptorlarining ekspressiyasini sezilarli 2.0-2.5 baravarga pasayishini koʻrsatdi. COVID-19 kasalligi barcha, yengil, oʻrtacha va ogʻir darajasi mavjud ayollarda ERα va PRA retseptorlari pasayishi aniqlandi. Xususan, yengil darajadagi kasallikda ERα va PRA ekspressiyasi oʻrtacha past aniqlangan boʻlsa, oʻrtacha va ogʻir darajadagi kasallik shakllarida bu koʻrsatkichlar sezilarli yaʼni 2,0-2,5 baravar past darajada aniqlandi. Kasallik retsidivini oldini olish va reproduktiv funksiyasini tiklash maqsadida oʻtkazilgan gormonal terapiya samaradorligini baholash maqsadida oʻtkazilgan takror IGK- tadqiqot natijalari, mikronizirlangan 0,060mg gestoden va 0,015 mg etinilestradiol saqlovchi preparat bilan 3 oy davolangan bemorlarda endometriy ERα va PRA retseptorlarining ekspressiyasining sezilarli 1.5 va 2.0 baravarga oshganini koʻrsatdi. Summary. The study included 60 women with menstrual cycle disorders associated with COVID-19. Among them, 20 patients had a mild form of COVID-19, 20 patients had a moderate form of COVID-19, and 20 patients had a severe form of COVID-19. The control group consisted of 20 healthy women. Studies have shown that women with menstrual and ovarian dysfunctions associated with COVID-19 experience a significant decrease in the expression of estrogen (ER) and progesterone (PR) receptors in the endometrium by 2.0-2.5 times. A reduction in ERα and PRA receptors was identified in all women with COVID-19, regardless of the severity of the disease: mild, moderate, and severe. Specifically, in cases of mild disease, the expression of ERα and PRA was moderately reduced, while in moderate and severe cases, these indicators were significantly lower, that is, by 2.0-2.5 times. Repeated immunohistochemical studies conducted to assess the effectiveness of hormone therapy aimed at preventing disease recurrence and restoring reproductive function showed that in patients treated with a drug containing micronized 0.060 mg gestodene and 0.015 mg ethinylestradiol for 3 months, the expression of ERα and PRA receptors in the endometrium significantly increased by 1.5 and 2.0 times.